FindTrial
Sign In

Sofosbuvir (SOF)

DRUG5 trials

Sponsors

AbbVie, Janssen Sciences Ireland UC, University of Colorado, Denver, Gilead Sciences

Conditions

Chronic Hepatitis C VirusChronic Hepatitis C Virus (HCV Infection Genotype 1)Hepatitis CHepatitis C VirusHepatitis C Virus InfectionHepatitis C, Chronic

Phase 2

A Study to Investigate the Pharmacokinetic Interactions Between Simeprevir and Ledipasvir in a Treatment Regimen Consisting of Simeprevir, Sofosbuvir, and Ledipasvir in Treatment-naive Participants With Chronic Hepatitis C Virus Genotype 1 Infection
CompletedNCT02421211
Janssen Sciences Ireland UCHepatitis C, Chronic
Start: 2015-05-19End: 2016-01-27Updated: 2019-03-28

Phase 3

Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir Co-Administered With Sofosbuvir With and Without Ribavirin in Treatment-Naive HCV Genotype 1-Infected Adults
CompletedNCT02399345
AbbVieChronic Hepatitis C Virus (HCV Infection Genotype 1)
Start: 2015-03-31End: 2015-11-30Updated: 2016-12-12
Reversal of Hepatic Impairment in Patients With Hepatitis C Virus (HCV) and Early Decompensation of Cirrhosis
TerminatedNCT02455167
University of Colorado, DenverHepatitis C
Start: 2015-05-31End: 2016-07-18Updated: 2021-09-13
A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adults With Genotype 2 Chronic Hepatitis C Virus Infection
CompletedNCT02723084
AbbVieChronic Hepatitis C Virus, Hepatitis C Virus
Start: 2016-04-08End: 2017-03-24Updated: 2021-07-16

Unknown Phase

A Registry for Adolescent and Pediatric Participants Who Received a Gilead Hepatitis C Virus Direct Acting Antiviral (DAA) in Gilead-Sponsored Chronic Hepatitis C Infection Trials
TerminatedNCT02510300
Gilead SciencesHepatitis C Virus Infection
Start: 2015-10-21End: 2023-01-06Updated: 2023-01-27

Related Papers

Long-term efficacy and safety of sofosbuvir-based direct-acting antiviral regimens in paediatric patients with hepatitis C virus infection: an international registry study.
2025-04-013 citations
Integrated analysis of 8-week glecaprevir/pibrentasvir in Japanese and overseas patients without cirrhosis and with hepatitis C virus genotype 1 or 2 infection
Journal of Gastroenterology2019-03-1319 citations
Integrated Resistance Analysis of CERTAIN-1 and CERTAIN-2 Studies in Hepatitis C Virus-Infected Patients Receiving Glecaprevir and Pibrentasvir in Japan
Antimicrobial Agents and Chemotherapy2017-11-2749 citations
Pharmacokinetic Interactions between Simeprevir and Ledipasvir in Treatment-Naive Hepatitis C Virus Genotype 1-Infected Patients without Cirrhosis Treated with a Simeprevir-Sofosbuvir-Ledipasvir Regimen
Antimicrobial Agents and Chemotherapy2017-10-038 citations